Huizhe Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huizhe Xu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Haozhe Piao
Department of Neurosurgery, Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, People’s Republic of China
5 shared publications - Haozhe Piao
Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China.
4 shared publications Ji Shi
Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China
3 shared publicationsQiang Liu
Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China
3 shared publicationsHaiyang Liang
Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China
2 shared publicationsHuilan Yang
Department of Hyperbaric Oxygen, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning Province, 110003, P R China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2031751
Editorial: Unlocking the potential of extracellular vesicles in tumor immunity and drug resistance
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2031751
Open AccessEditorial: Unlocking the potential of extracellular vesicles in tumor immunity and drug resistance
- Open Access
- 23 June 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (5)
Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway
Gliomas are aggressive tumors with poor treatment outcomes. Tasimelteon, an FDA-approved melatonin receptor agonist with favorable blood-brain barrier penetration, has unexplored anti-tumor potential. This study investigated whether Tasimelteon inhibits glioma proliferation through ferroptosis induction. Cell viability, colony formation, and immunofluorescence were employed to assess the effects of Tasimelteon on glioma cells. Ferroptosis was assessed by measuring lipid peroxidation markers (MDA, 4-HNE, BODIPY 581/591 C11) and ROS levels, and mitochondrial damage was detected by TEM. Mechanisms were examined through Western blotting, qPCR, dual-luciferase reporter assays, site-directed mutagenesis and molecular docking. In vivo, LN229-Luc glioma cells were orthotopically injected into mouse brains, followed by Tasimelteon treatment. Tumor growth was monitored by bioluminescence imaging, and body weight and survival were recorded. Systemic toxicity was evaluated through H&E staining of major organs. Tasimelteon decreased glioma cell viability and colony formation in dose- and time-dependent manners. Mechanistically, Tasimelteon induced ferroptosis, characterized by elevated lipid peroxidation markers (MDA, 4-HNE) and ROS levels, along with mitochondrial damage observed by TEM. This process was accompanied by ACSL4 upregulation. Further investigation revealed that Tasimelteon bound to SP1 at Gln465 and Leu467 residues, stabilizing the protein and enhancing ACSL4 transcription, independent of MT1/MT2 receptor activation. In orthotopic glioma models, Tasimelteon suppressed tumor growth by inducing ferroptosis and prolonged survival without systemic toxicity. Tasimelteon inhibits glioma growth by inducing ferroptosis via the SP1/ACSL4 pathway, offering a novel therapeutic approach.
- 23 June 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (5)
Open AccessTasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway
Gliomas are aggressive tumors with poor treatment outcomes. Tasimelteon, an FDA-approved melatonin receptor agonist with favorable blood-brain barrier penetration, has unexplored anti-tumor potential. This study investigated whether Tasimelteon inhibits glioma proliferation through ferroptosis induction. Cell viability, colony formation, and immunofluorescence were employed to assess the effects of Tasimelteon on glioma cells. Ferroptosis was assessed by measuring lipid peroxidation markers (MDA, 4-HNE, BODIPY 581/591 C11) and ROS levels, and mitochondrial damage was detected by TEM. Mechanisms were examined through Western blotting, qPCR, dual-luciferase reporter assays, site-directed mutagenesis and molecular docking. In vivo, LN229-Luc glioma cells were orthotopically injected into mouse brains, followed by Tasimelteon treatment. Tumor growth was monitored by bioluminescence imaging, and body weight and survival were recorded. Systemic toxicity was evaluated through H&E staining of major organs. Tasimelteon decreased glioma cell viability and colony formation in dose- and time-dependent manners. Mechanistically, Tasimelteon induced ferroptosis, characterized by elevated lipid peroxidation markers (MDA, 4-HNE) and ROS levels, along with mitochondrial damage observed by TEM. This process was accompanied by ACSL4 upregulation. Further investigation revealed that Tasimelteon bound to SP1 at Gln465 and Leu467 residues, stabilizing the protein and enhancing ACSL4 transcription, independent of MT1/MT2 receptor activation. In orthotopic glioma models, Tasimelteon suppressed tumor growth by inducing ferroptosis and prolonged survival without systemic toxicity. Tasimelteon inhibits glioma growth by inducing ferroptosis via the SP1/ACSL4 pathway, offering a novel therapeutic approach.
- Open Access
- 25 March 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14
Editorial: Research on nanomaterials in tumor diagnosis and therapy, volume II
- 25 March 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14
Open AccessEditorial: Research on nanomaterials in tumor diagnosis and therapy, volume II
- Open Access
- 14 November 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (11) , 43051
Advances in the Study of Intestinal Microbiota and Neuropathic Pain
The intestinal microbiota, present in vast numbers within the human body, plays a pivotal role, with its composition and abundance varying significantly across individuals. This gut microbiota not only contributes to normal physiological development but also impacts the initiation, progression, resolution, and prognosis of various diseases. Recent studies have increasingly illuminated the connection between intestinal microbiota and pain, with a particular focus on the relationship between gut microbiota and neuropathic pain (NP). NP, an acute and chronic pain disorder arising from sensory nervous system injury, encompasses both peripheral and central neuropathic pain. Evidence suggests that intestinal microbiota influences NP occurrence and may modulate its severity. This review synthesizes current research findings on the microbiota-NP relationship, aiming to establish a theoretical foundation for future clinical investigations.
- 14 November 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (11) , 43051
Open AccessAdvances in the Study of Intestinal Microbiota and Neuropathic Pain
The intestinal microbiota, present in vast numbers within the human body, plays a pivotal role, with its composition and abundance varying significantly across individuals. This gut microbiota not only contributes to normal physiological development but also impacts the initiation, progression, resolution, and prognosis of various diseases. Recent studies have increasingly illuminated the connection between intestinal microbiota and pain, with a particular focus on the relationship between gut microbiota and neuropathic pain (NP). NP, an acute and chronic pain disorder arising from sensory nervous system injury, encompasses both peripheral and central neuropathic pain. Evidence suggests that intestinal microbiota influences NP occurrence and may modulate its severity. This review synthesizes current research findings on the microbiota-NP relationship, aiming to establish a theoretical foundation for future clinical investigations.
- Open Access
- 10 October 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 56 (6) , 1-28
Research progress on TMEM proteins in cancer progression and chemoresistance (Review)
In cancer research, the transmembrane (TMEM) family of proteins has attracted considerable attention due to its role in tumor progression and chemoresistance. These membrane proteins are integral to cellular processes, including signal transduction, ion transport and cellular homeostasis, rendering them promising therapeutic targets. The TMEM proteins are implicated in several types of cancer, including breast, ovarian, lung and thyroid cancer, where they regulate numerous cellular processes, including proliferation, migration, invasion and survival. Notably, TMEM45A and TMEM158 contribute to resistance to platinum‑based chemotherapy by increasing the expression of proteins associated with hypoxic conditions and multidrug resistance. Additionally, epigenetic regulation, particularly promoter methylation of TMEM88, is pivotal in regulating TMEM88 expression and function in chemoresistance. The present review presents a systematic and comprehensive overview of the structural features, biological functions and regulatory mechanisms of key TMEM proteins across various types of cancer. It also highlights emerging connections between TMEM proteins and the tumor microenvironment, emphasizing their potential as promising therapeutic targets. The novel findings underscore the key role of the TMEM protein family in overcoming chemoresistance and lay a foundation for the development of targeted therapeutic strategies in cancer treatment.
- 10 October 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 56 (6) , 1-28
Open AccessResearch progress on TMEM proteins in cancer progression and chemoresistance (Review)
In cancer research, the transmembrane (TMEM) family of proteins has attracted considerable attention due to its role in tumor progression and chemoresistance. These membrane proteins are integral to cellular processes, including signal transduction, ion transport and cellular homeostasis, rendering them promising therapeutic targets. The TMEM proteins are implicated in several types of cancer, including breast, ovarian, lung and thyroid cancer, where they regulate numerous cellular processes, including proliferation, migration, invasion and survival. Notably, TMEM45A and TMEM158 contribute to resistance to platinum‑based chemotherapy by increasing the expression of proteins associated with hypoxic conditions and multidrug resistance. Additionally, epigenetic regulation, particularly promoter methylation of TMEM88, is pivotal in regulating TMEM88 expression and function in chemoresistance. The present review presents a systematic and comprehensive overview of the structural features, biological functions and regulatory mechanisms of key TMEM proteins across various types of cancer. It also highlights emerging connections between TMEM proteins and the tumor microenvironment, emphasizing their potential as promising therapeutic targets. The novel findings underscore the key role of the TMEM protein family in overcoming chemoresistance and lay a foundation for the development of targeted therapeutic strategies in cancer treatment.
- Open Access
- 31 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 144, 156917
Ginsenoside F2-modified liposomes delivering FTY720 enhance glioblastoma targeting and antitumor activity via ferroptosis
- 31 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 144, 156917
Open AccessGinsenoside F2-modified liposomes delivering FTY720 enhance glioblastoma targeting and antitumor activity via ferroptosis
- Open Access
- 11 April 2025
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66 (5) , 1-17
Targeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol
Glioblastoma (GBM) is a disease with high morbidity and poor prognosis. The combination of traditional Chinese and Western medicine and cuproptosis are known to serve important roles in the treatment of GBM. However, targeting cuproptosis to treat GBM by combining traditional Chinese and Western medicine has not been extensively investigated. Therefore, the present study focused on the diagnosis and treatment of GBM based on cuproptosis. Through a bioinformatics approach, a cuproptosis‑related prognostic model was first constructed. Next, this prognostic model was found to be closely related to immune infiltration, DNA mutation and DNA methylation through multi‑omics analysis. The present study indicated the cell clusters in GBM tissues and the risk scores in each cluster based on single‑cell sequencing data derived from Gene Expression Omnibus. Notably, by screening the CellMiner database, EMD‑1204831 was found to exhibit a high correlation with the risk score. Next, through network pharmacology and molecular docking analysis, the risk score‑related gene collagen type XXII α1 chain (COL22A1) was identified as the target of kaempferol, which is the active component of Ginseng. Notably, kaempferol could decrease the proliferation of GBM cells by inhibiting COL22A1 expression in cell experiments. Finally, kaempferol and EMD‑1204831 had an obvious inhibitory effect on the growth of GBM and sensitized GBM to cuproptosis inducers via COL22A1 in cell and animal experiments. Overall, the present study revealed a cuproptosis‑related combined regimen for GBM.
- 11 April 2025
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66 (5) , 1-17
Open AccessTargeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol
Glioblastoma (GBM) is a disease with high morbidity and poor prognosis. The combination of traditional Chinese and Western medicine and cuproptosis are known to serve important roles in the treatment of GBM. However, targeting cuproptosis to treat GBM by combining traditional Chinese and Western medicine has not been extensively investigated. Therefore, the present study focused on the diagnosis and treatment of GBM based on cuproptosis. Through a bioinformatics approach, a cuproptosis‑related prognostic model was first constructed. Next, this prognostic model was found to be closely related to immune infiltration, DNA mutation and DNA methylation through multi‑omics analysis. The present study indicated the cell clusters in GBM tissues and the risk scores in each cluster based on single‑cell sequencing data derived from Gene Expression Omnibus. Notably, by screening the CellMiner database, EMD‑1204831 was found to exhibit a high correlation with the risk score. Next, through network pharmacology and molecular docking analysis, the risk score‑related gene collagen type XXII α1 chain (COL22A1) was identified as the target of kaempferol, which is the active component of Ginseng. Notably, kaempferol could decrease the proliferation of GBM cells by inhibiting COL22A1 expression in cell experiments. Finally, kaempferol and EMD‑1204831 had an obvious inhibitory effect on the growth of GBM and sensitized GBM to cuproptosis inducers via COL22A1 in cell and animal experiments. Overall, the present study revealed a cuproptosis‑related combined regimen for GBM.
- Open Access
- 26 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-2
Correction: Metabolism: an important player in glioma survival and development
- 26 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-2
Open AccessCorrection: Metabolism: an important player in glioma survival and development
- Open Access
- 8 January 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 12, 1526612
Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy
Cancer is a major killer threatening modern human health and a leading cause of death worldwide. Due to the heterogeneity and complexity of cancer, traditional treatments have limited effectiveness. To address this problem, an increasing number of researchers and medical professionals are working to develop new ways to treat cancer. Bacteria have chemotaxis that can target and colonize tumor tissue, as well as activate anti-tumor immune responses, which makes them ideal for biomedical applications. With the rapid development of nanomedicine and synthetic biology technologies, bacteria are extensively used as carriers for drug delivery to treat tumors, which holds the promise of overcoming the limitations of conventional cancer treatment regimens. This paper summarizes examples of anti-cancer drugs delivered by bacterial carriers, and their strengths and weaknesses. Further, we emphasize the promise of bacterial carrier delivery systems in clinical translation.
- 8 January 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 12, 1526612
Open AccessBacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy
Cancer is a major killer threatening modern human health and a leading cause of death worldwide. Due to the heterogeneity and complexity of cancer, traditional treatments have limited effectiveness. To address this problem, an increasing number of researchers and medical professionals are working to develop new ways to treat cancer. Bacteria have chemotaxis that can target and colonize tumor tissue, as well as activate anti-tumor immune responses, which makes them ideal for biomedical applications. With the rapid development of nanomedicine and synthetic biology technologies, bacteria are extensively used as carriers for drug delivery to treat tumors, which holds the promise of overcoming the limitations of conventional cancer treatment regimens. This paper summarizes examples of anti-cancer drugs delivered by bacterial carriers, and their strengths and weaknesses. Further, we emphasize the promise of bacterial carrier delivery systems in clinical translation.
- Open Access
- 22 October 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-27
Metabolism: an important player in glioma survival and development
Gliomas are malignant tumors originating from both neuroglial cells and neural stem cells. The involvement of neural stem cells contributes to the tumor’s heterogeneity, affecting its metabolic features, development, and response to therapy. This review provides a brief introduction to the importance of metabolism in gliomas before systematically categorizing them into specific groups based on their histological and molecular genetic markers. Metabolism plays a critical role in glioma biology, as tumor cells rely heavily on altered metabolic pathways to support their rapid growth, survival, and progression. Dysregulated metabolic processes, involving carbohydrates, lipids, and amino acids not only fuel tumor development but also contribute to therapy resistance and metastatic potential. By understanding these metabolic changes, key intervention points, such as mutations in genes like RTK, EGFR, RAS, and IDH can be identified, paving the way for novel therapeutic strategies. This review emphasizes the connection between metabolic pathways and clinical challenges, offering actionable insights for future research and therapeutic development in gliomas.
- 22 October 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-27
Open AccessMetabolism: an important player in glioma survival and development
Gliomas are malignant tumors originating from both neuroglial cells and neural stem cells. The involvement of neural stem cells contributes to the tumor’s heterogeneity, affecting its metabolic features, development, and response to therapy. This review provides a brief introduction to the importance of metabolism in gliomas before systematically categorizing them into specific groups based on their histological and molecular genetic markers. Metabolism plays a critical role in glioma biology, as tumor cells rely heavily on altered metabolic pathways to support their rapid growth, survival, and progression. Dysregulated metabolic processes, involving carbohydrates, lipids, and amino acids not only fuel tumor development but also contribute to therapy resistance and metastatic potential. By understanding these metabolic changes, key intervention points, such as mutations in genes like RTK, EGFR, RAS, and IDH can be identified, paving the way for novel therapeutic strategies. This review emphasizes the connection between metabolic pathways and clinical challenges, offering actionable insights for future research and therapeutic development in gliomas.